Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
The results of the real-world REFINE study confirmed the safety and effectiveness of regorafenib in a broad population of patients with uHCC. Of patients who received standard regorafenib dosing in REFINE, safety and efficacy findings were consistent with those reported in the RESORCE trial.
Authors
- Philippe Merle (ORCID: https://orcid.org/0000-0002-8230-394X)
- Guoliang Shao (ORCID: https://orcid.org/0000-0003-2121-9194)
- Ho Yeong Lim (ORCID: https://orcid.org/0000-0001-9325-2300)
- Masafumi Ikeda (ORCID: https://orcid.org/0000-0002-4050-2086)
- Alessandro Granito (ORCID: https://orcid.org/0000-0002-0637-739X)
- Kazushi Numata (ORCID: https://orcid.org/0000-0003-4671-4431)
- Masatoshi Kudo (ORCID: https://orcid.org/0000-0002-4102-3474)
- Naoya Kato (ORCID: https://orcid.org/0000-0001-5812-2818)
- Heinz‐Josef Klümpen (ORCID: https://orcid.org/0000-0002-7290-1823)
- Matthias Pinter (ORCID: https://orcid.org/0000-0002-7260-532X)
- Kangshun Zhu (ORCID: https://orcid.org/0000-0001-5142-010X)
- Philip Twumasi‐Ankrah
- Gianluca Masi (ORCID: https://orcid.org/0000-0001-8329-8989)
- Sung Bum Cho (ORCID: https://orcid.org/0000-0001-9816-3446)
- Yilei Mao
- Javeed Khan
- Yi‐Hsiang Huang (ORCID: https://orcid.org/0000-0001-5241-5425)
- Richard S. Finn (ORCID: https://orcid.org/0000-0003-2494-2126)
- Kirhan Özgürdal (ORCID: https://orcid.org/0000-0003-3812-0692)
- René Gerolami
- Masayuki Kurosaki (ORCID: https://orcid.org/0000-0001-7016-8931)
- Chih‐Hung Hsu (ORCID: https://orcid.org/0000-0003-0495-973X)
- Do Young Kim (ORCID: https://orcid.org/0000-0002-8327-3439)
- Yoon Jun Kim (ORCID: https://orcid.org/0000-0001-9141-7773)
- Shukui Qin (ORCID: https://orcid.org/0000-0001-9772-132X)
- Shi-Ming Lin
- Long‐Bin Jeng (ORCID: https://orcid.org/0000-0002-4588-2268)
- Yih‐Jyh Lin
- Maria Awan
- Kung‐Kai Kuo
Institutions
- Nanjing University of Chinese Medicine (CN)
- National Yang Ming Chiao Tung University (TW)
- Bayer (United States) (US)
- University of California, Los Angeles (US)
- China Medical University (TW)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Severance Hospital (KR)
- Peking Union Medical College Hospital (CN)
- Yokohama City University Medical Center (JP)
- Samsung Medical Center (KR)
- New Generation University College (ET)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
- Seoul National University Hospital (KR)
- Taipei Veterans General Hospital (TW)
- Hôpital de la Croix-Rousse (FR)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Chiba University Hospital (JP)
- Linkou Chang Gung Memorial Hospital (TW)
- Bayer (Switzerland) (CH)
- Azienda USL di Bologna (IT)
- China Medical University Hospital (TW)
- National Taiwan University Hospital (TW)
- National Cancer Center Hospital East (JP)
- Chonnam National University Hwasun Hospital (KR)
- Musashino Red Cross Hospital (JP)
- Amsterdam University Medical Centers (NL)
- National Cheng Kung University Hospital (TW)
- Hôpital de la Timone (FR)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Bayer (United Kingdom) (GB)
- Medical University of Vienna (AT)
- Sungkyunkwan University (KR)
- University of Amsterdam (NL)
- Yokohama City University (JP)
- Kindai University (JP)
- National Cheng Kung University (TW)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Liver Cancer
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1159/000542285
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.22
Funders
- European Commission